Pamoic acid
Based on 5 publication(s) in Google Scholar
Pamoic acid (Embonic acid) is a potent GPR35 agonist with an EC50 of 79 nM. Pamoic acid exhibits neuroprotective and anti-inflammatory properties.
For research use only. We do not sell to patients.
- Purity: 99.69%
- CAS No.: 130-85-8
- Formula: C23H16O6
- Molecular Weight:388.38
-
Storage:
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications Citing Use of MedChemExpress (MCE) Pamoic acid
More
Biological Activity
EC50: 79 nM (GPR35)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
0.05 μM
Compound: 4
|
Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay
|
[PMID: 23713606] |
| CHO | EC50 |
1.2 μM
Compound: 9
|
Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells after 90 mins by beta-arrestin recruitment assay
Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells after 90 mins by beta-arrestin recruitment assay
|
[PMID: 23888932] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 130-85-8
-
Appearance Solid
-
Molecular Weight 388.38
-
Formula C23H16O6
-
Color Light yellow to yellow
-
SMILES
OC1=C(C(O)=O)C=C2C(C=CC=C2)=C1CC3=C(O)C(C(O)=O)=CC4=C3C=CC=C4
-
Synonyms
Embonic acid
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Clin Transl Med
EEPD1 regulates inflammation and endothelial apoptosis in atherosclerosis through KLF4-EEPD1-ERK axis. [Abstract]2025 Apr;15(4):e70311. PMID: 40268512 -
Eur J Med Chem
2024 Dec 5:279:116842. PMID: 39260319 -
Noncoding RNA Res
Tongue squamous cell carcinoma-derived exosomes miR-21-5p affect tumor progression via promoting M2 macrophage polarization. [Abstract]2025 May 15:13:184-196. PMID: 40519608 -
Int Immunopharmacol
Eupatilin suppresses osteoclastogenesis and periodontal bone loss by inhibiting the MAPKs/Siglec-15 pathway. [Abstract]2024 Jul 23:139:112720. PMID: 39047450 -
Curr Eye Res
Kisspeptin Suppresses the Growth of Primary Pterygial Cells via Inhibiting Chemokine (C-X-C Motif) Ligands in Microenvironment. [Abstract]2025 Jun 24:1-9. PMID: 40555256
Solvent & Solubility
DMSO : 50 mg/mL (128.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ozayra Sharmin, et al. Activation of GPR35 protects against cerebral ischemia by recruiting monocyte-derived macrophages. Sci Rep. 2020 Jun 10;10(1):9400. [Content Brief]
[2]. Pingwei Zhao, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5748 mL | 12.8740 mL | 25.7480 mL | 64.3699 mL |
| 5 mM | 0.5150 mL | 2.5748 mL | 5.1496 mL | 12.8740 mL | |
| 10 mM | 0.2575 mL | 1.2874 mL | 2.5748 mL | 6.4370 mL | |
| 15 mM | 0.1717 mL | 0.8583 mL | 1.7165 mL | 4.2913 mL | |
| 20 mM | 0.1287 mL | 0.6437 mL | 1.2874 mL | 3.2185 mL | |
| 25 mM | 0.1030 mL | 0.5150 mL | 1.0299 mL | 2.5748 mL | |
| 30 mM | 0.0858 mL | 0.4291 mL | 0.8583 mL | 2.1457 mL | |
| 40 mM | 0.0644 mL | 0.3218 mL | 0.6437 mL | 1.6092 mL | |
| 50 mM | 0.0515 mL | 0.2575 mL | 0.5150 mL | 1.2874 mL | |
| 60 mM | 0.0429 mL | 0.2146 mL | 0.4291 mL | 1.0728 mL | |
| 80 mM | 0.0322 mL | 0.1609 mL | 0.3218 mL | 0.8046 mL | |
| 100 mM | 0.0257 mL | 0.1287 mL | 0.2575 mL | 0.6437 mL |